Alnylam’s RNAi therapeutic Onpattro has been approved for use in Europe to treat adults with stage 1 or stage 2 polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.